Company · Public · UBX
Unity Biotechnology
Clinical-stage company developing medicines that selectively clear senescent cells, historically focused on ophthalmology and localized delivery.
EvidenceModerateDurability data in line
Listing
Public
Ticker
UBX
Headquarters
South San Francisco, US
Founded
2011
Technology
Senolytics
Category
Market cap
$0.1B
Longevity thesis
Local senolytic delivery avoids the systemic tolerability problems that have limited earlier senolytic candidates.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| UBX1325 | Phase 2b | Diabetic macular edema |
| UBX2050 | Preclinical | Ocular fibrosis |
Recent developments
- 19 Jul 2026Reported 36-week durability data in diabetic macular edema.
- 5 Mar 2026Reduced discovery spend to extend cash runway.
Scientific evidence
EvidenceModerate
Human data exist but in a narrow indication. Positive results validate senolytic mechanism only in the eye.
LONGEFI analysis
The most direct public-market read on senolytics, though the company's size means the share price reflects trial risk far more than the underlying biology.
Analysis is research commentary. It is not investment advice or a recommendation.